Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
358 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07838714 | Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia | recruiting | Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)(SOBER) | terminated | Phase 2 | 78 | Ruijin HospitalOTHER | 1 | Sep 23, 2026 |
| clinicaltrials |
| NCT07824479 | Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer | recruiting | — | 120 | Ruijin HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07813260 | Screening for Urological Malignancies Using a Urine Exfoliated Cell Fluorescence Assay in a Hematuria Population | recruiting | — | 170 | Ruijin HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06767891 | Real-world Study of Acalabrutinib(RESA) | enrolling by invitation | — | 160 | Ruijin HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07795528 | Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma(ADX-DRIVER-CRC) | recruiting | — | 392 | Ruijin HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07776899 | Clinical Applications of FAPI PET in Solid Tumors | recruiting | N/A | 200 | Ruijin HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07774572 | Exploration of Circular RNA in B-cell Hematologic Malignancies | recruiting | Phase 1 | 30 | Ruijin HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05277688 | Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients | recruiting | Phase 3 | 340 | Ruijin HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07025889 | IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer | recruiting | Phase 1 / Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05552846 | Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy | recruiting | N/A | 104 | Ruijin HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04517266 | Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer | recruiting | N/A | 214 | Ruijin HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06583655 | Precision Regional Node Irradiation for Sentinel Node-positive Breast Cancer | active not recruiting | N/A | 205 | Ruijin HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06596954 | Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma | recruiting | N/A | 212 | Ruijin HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07680582 | An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors | recruiting | Early Phase 1 | 60 | Ruijin HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | recruiting | Phase 2 | 205 | Ruijin HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07736131 | Learning Curve of SILS in CRC(SILS) | completed | — | 280 | Ruijin HospitalOTHER | 0 | Jul 30, 2026 | clinicaltrials |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | not yet recruiting | Phase 3 | 168 | Ruijin HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | recruiting | Phase 2 | 25 | Ruijin HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma | not yet recruiting | Phase 3 | 652 | Ruijin HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07717177 | AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL(PRAISE) | not yet recruiting | Phase 2 | 112 | Ruijin HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07527689 | Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer(HARVEST-PRO) | recruiting | N/A | 1,950 | Ruijin HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07638787 | Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL | not yet recruiting | Phase 1 / Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07672964 | CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation(CD45RADLIPx) | not yet recruiting | Phase 1 | 30 | Ruijin HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07664787 | Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study(STAR) | not yet recruiting | N/A | 20 | Ruijin HospitalOTHER | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07662369 | CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation(CD45RADLITx) | recruiting | Phase 1 / Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07657572 | A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.(EXCELLENT) | not yet recruiting | — | 1,000 | Ruijin HospitalOTHER | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07649928 | A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 24 | Ruijin HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07628738 | A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy | recruiting | Phase 2 | 39 | Ruijin HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07613788 | Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL | not yet recruiting | Phase 2 | 100 | Ruijin HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06587061 | HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07131514 | HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07180966 | Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation(SAH) | completed | — | 780 | Ruijin HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07602322 | LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure | not yet recruiting | Phase 2 | 60 | Ruijin HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07594899 | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL(GUIDANCE-10) | not yet recruiting | Phase 2 | 178 | Ruijin HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07589361 | Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors(VBS-CSI-PT-PED) | not yet recruiting | — | 38 | Ruijin HospitalOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07584850 | Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Early Phase 1 | 9 | Ruijin HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT05018520 | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk | recruiting | Phase 3 | 640 | Ruijin HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07514169 | The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL(SILVERGLO) | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07554742 | Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging | not yet recruiting | — | 64 | Ruijin HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07548255 | The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL | not yet recruiting | Phase 1 | 28 | Ruijin HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07543107 | Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast Cancer(OFFLINE-PET-PR) | not yet recruiting | — | 30 | Ruijin HospitalOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07537712 | Proton vs Photon IMRT Toxicity in Breast Cancer(PPTOX-BC) | not yet recruiting | — | 750 | Ruijin HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials